Discrepancies between in silico and in vitro data in the functional analysis of a breast cancer-associated polymorphism in the XRCC6/Ku70 gene. by MARRAS E et al.
Abstract. Previous results from our research group have
shown that the c.-1310 CG single nucleotide polymorphism in
the promoter region of the XRCC6/Ku70 gene is significantly
associated with breast cancer in a sample human patient
population. In an attempt to attribute a functional meaning to
this polymorphism, we performed a thorough analysis using
a number of established in silico tools that strongly suggested
that the c.-1310CG transversion would activate a cryptic
splicing acceptor located upstream of the canonical promoter
of Ku70, but downstream of a putative alternative promoter
(PAP) of the same gene. Experimental investigation of
alternative transcripts, as well as of the activity of the PAP
detected in silico, did not support the initial hypothesis of a
functional role of the c.-1310CG mutation in alternative
splicing. Although a functional role of the SNP has yet to be
determined, some evidence points to the linkage dis-
equilibrium of the G variant of the polymorphism, with
mutations located at critical sites within the promoter region
of Ku70.
Introduction
Breast cancer is a major public health issue worldwide.
Globally, it is by far the most frequent cancer in women, with
an estimated 1.15 million new cases in 2002 (23% of all
cancers), and more than half of these cases occurring in the
industrialized countries of Europe and North America (1). In
Europe in 2006, breast cancer accounted for 28.9% of all
cancer cases in women, and was the leading cause of cancer-
related death within the European Union (16.7%) (2).
In several independent studies also conducted by our
group, an enhanced in vitro chromosomal radiosensitivity
was observed in a significant number of breast cancer patients
(3-7). Since the most detrimental form of radiation-induced
DNA damage is the double-strand break (DSB), it is plausible
that DSB-initiated chromosomal instability drives breast
carcinogenesis. Furthermore, the key breast cancer suscep-
tibility genes, BRCA1 and BRCA2, ATM and TP53, play
important roles in DSB repair and chromosome stability
(8,9). These genetic factors are present in only 6-11% of the
general breast cancer patient population, indicating that other
mutations in low penetrant genes or subtle defects arising
from low penetrant variations in highly penetrant genes may
also create a predisposition to breast cancer (9-12). Recently,
several population-based case-control studies have shown a
link between single nucleotide polymorphisms (SNPs) in DSB
repair genes and breast cancer risk (8,9,12-17). Moreover, the
breast is a selected microenvironment, subjected to endoge-
nous oxidative stress through hormone exposure. Estrogen in
particular has attracted considerable attention, as it may act as
a complete carcinogen (8). During the oxidative metabolism of
estrogen, reactive oxygen species (ROS) and DNA adducts are
formed, leading to the oxidation and depurination of the DNA
(18). This type of damage can further result in clustered sites
of DNA damage, including DSBs. DSBs are also induced in
proliferating cells when the replication fork encounters single-
stranded DNA damage (19). Thus, estrogen plays a dual role
as a growth-stimulating hormone and strand break-inducing
agent, which may explain why DSB repair is so important in
breast tumorigenesis.
The two main mechanisms of DSB repair are homologous
recombination (HR) and non-homologous end-joining (NHEJ)
(reviewed in ref. 19). Which pathway is activated in eukaryotic
cells depends primarily on the cell cycle stage. The more
accurate HR pathway is activated in S/G2, when the sister
chromatid provides a perfect copy of the sequence for align-
ment, while the more error-prone NHEJ pathway is the
favoured mechanism in resting cells (G0/G1) (20). NHEJ is
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also the main mechanism for repairing radiation-induced
DSBs in mammalian cells (21). Defects in this pathway result
in enhanced chromosomal radiosensitivity, which is a hallmark
for breast cancer. In NHEJ, broken DNA termini are first
processed to make them compatible and then sealed by a
ligation step, which often results in the loss of a few nucleo-
tides at the broken ends. The key protein components of NHEJ
(20) include the catalytic subunit of DNA protein kinase
(DNA-PKCS), the two regulatory subunits of the DNA-PK
complex Ku70 and Ku80, DNA ligase IV with its cofactor
XRCC4 (the X-ray cross complementing group 4 protein) and
the nuclease artemis. The Ku70/Ku80 (Ku) heterodimer is
the first protein to bind to the damaged ends of a DSB. When
bound to DNA, Ku recruits and activates DNA-PKCS. As these
proteins play a prominent role in DNA DSB repair, they are
vital for genome stability and act as tumour suppressors.
Severe defects in these genes result in a high level of genetic
instability and lead to cell death, triggered by cell cycle
checkpoint surveillance. However, if these genes harbour
small variations, such as SNPs, which result in mild defects
that escape checkpoint surveillance, the resulting suboptimal
DNA DSB-repair could allow the accumulation of DNA
damage, possibly leading to chromosomal instability and
tumorigenesis (12).
In our previous studies, we investigated the association
between SNPs in NHEJ genes and breast cancer susceptibility.
A positive association was found between the variant allele
of the c.-1310 CG SNP in Ku70 and breast cancer, with a
significant odds ratio (ORHe = 1.85; p=0.048) observed in
sporadic breast cancer patients. In familial breast cancer
patients the positive OR was not significant, which could
indicate that other environmental factors, besides genetic
aptitude, modify the association between the c.-1310 CG
SNP in Ku70 and breast cancer (17). The possible effect of
estrogen exposure was examined in an enlarged unselected
patient population. A significant OR of 1.69 (p=0.017) was
found for the total patient population. By dividing the patient
population into smaller groups based on estrogen exposure
parameters, high and significant ORs were observed for
patients with a longer estrogen exposure (early age at first
menarche, ORHe+HV = 1.84, p=0.008; late age at menopause,
ORHe+HV = 1.96, p=0.029; long exposure interval, ORHe+HV =
1.81, p=0.035), while the ORs of patients with a short estrogen
exposure were lower and non-significant (Willems et al,
unpublished data). Besides being involved in breast cancer
predisposition, the c.-1310 CG SNP in Ku70 has also been
implicated in in vivo chromosomal radiosensitivity after
radiation therapy in head and neck cancer patients. Carriers of
the variant G allele show a 4-fold increased risk of developing
severe dysphagia (Werbrouck et al, unpublished data).
These results suggest that the c.-1310 CG SNP located in
the promoter region of Ku70 might influence DSB repair, and
prompted us to investigate the possible functional role of this
mutation at the molecular level using in silico and in vitro
molecular techniques.
Materials and methods
Cell cultures. The EBV-immortalized lymphoblastic cell lines
C002, C003 and C025 from healthy donors, as well as a panel
of an additional 23 cell lines all homozygous for the ‘C’ variant
of the c.-1310CG SNP, were obtained from the cultured cell
bank of the Department of Basic Medical Sciences, Ghent
University, Ghent, Belgium. The EBV-immortalized GM12802
cell line, homozygous for the ‘G’ variant of c.-1310CG
SNP, was purchased from Coriell Cell Repositories, NJ,
USA. This panel of lymphoblastoid cell lines was used to
assess chromosomal radiosensitivity by cytogenetic tests, to
amplify specific sequences within the promoter region of
XRCC6/ Ku70, and to screen the transcript variants of Ku70.
The COS-7 cell line and the HEK 293 cell line (Istituto
Zooprofilattico, Brescia, Italy) were used to test promoter
sequences with the DLR Luciferase Reporter Assay System
(Promega, Italy). Lymphoblastoid cell lines were maintained
in RPMI-1640 medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml
streptomycin and 10% FBS. COS-7 and HEK 293 cells were
cultured in Dulbecco's modified Eagle's medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate
and 0.1 mM MEM Non-Essential Amino Acids Solution. All
cell lines were grown at 37˚C in 5% CO2 in a humidified
incubator.
RT-PCR analysis. Total RNA was isolated from 107 lympho-
blastoid cells using the SV Total RNA Isolation System
(Promega) according to the manufacturer's instructions. A 2-
to 3-μg aliquot of total RNA was used to generate single-
stranded cDNA and to amplify transcript fragments using the
RobusT II RT-PCR Kit (Finnzymes, Italy) under the following
conditions: 48˚C for 30 min followed by 94˚C for 2 min (first-
strand cDNA synthesis), 35 PCR amplification cycles (94˚C,
30 sec; 60˚C, 60 sec; 72˚C, 60 sec) and a final extension step
at 72˚C for 7 min. To detect hypothetical transcript variants,
primers were designed as described below. To amplify a
normal transcript fragment of XRCC6/Ku70 (NCBI accession
no. NM_001469.3), the following primers were used: primer 2
(5'-ACACTGGATGCTCA-3'), a common reverse primer that
annealed a specific sequence within Ku70 exon 2, and forward
primer 1 (5'-CATGCGTGGATTGTC-3') to give an amplified
product of 264 base pairs. To detect fragments generated by
alternative splicing, we designed forward primer 3 (5'-GCG
CCACCCTCTG-3'), forward primer 4 (5'-ATGTGAAGC
CAAATA-3') and forward primer 5 (5'-TCCTGGCCATGT
GT-3') to be used with reverse primer 2. RT-PCR products
were analyzed on 2.5% agarose gel, and the fragments of
interest were analyzed by enzymatic restriction digestion and
automated sequencing.
Construction of expression vectors. Human genomic DNA
was purified from 107 immortalized lymphoblasts using the
Jetquick Blood & Cell Culture DNA System (Genomed
GmbH, Germany) according to the manufacturer's instructions.
For the construction of reporter plasmids containing the canon-
ical sequence promoter of human Ku70 (http://genomics.
senescence.info/genes/seq.php?id=0117&type=promo), 2 μg
genomic DNA was used as a template for amplification of a
region of 748 bp spanning from position -1418 to -670,
upstream of the translation start site of XRCC6/Ku70 (5'-AGA
TGGCCCAAACTTCAGACC-3'; 5'-GGAAGCGACCAACTT
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GGACA-3' forward and reverse primers, respectively).
Similarly, a putative alternative promoter (PAP) region of
601 bp, spanning from position -2814 to -2213 upstream of the
transcription start site of XRCC6/Ku70, was amplified (5'-AGG
CCCAAATCCCTGTCAAATA-3' forward primer; 5'AGT
TCATCTCTGTGAGACGAGGG-3' reverse primer). All
sequences were generated using 0.02 U Fusion High-Fidelity
DNA Polymerase (Finnzymes) under the following conditions:
98˚C for 1 min followed by 35 amplification cycles (98˚C,
30 sec; 62˚C, 1 min; 72˚C, 30 sec) and by a final extension step
at 72˚C for 10 min. The fragments containing both the canon-
ical promoter and the PAP were subcloned into the SmaI site
of pBluescript II SK(-) (Stratagene, USA) and subsequently
subcloned into the pGL3 basic vector (XhoI and HindIII sites)
upstream of the firefly luciferase reporter gene, thus generating
the pGL3/canonical_promoter vector and the pGL3/PAP
vector. Correct cloning was confirmed by restriction enzyme
mapping and sequencing.
Transient transfection and reporter gene assays. Transfection
experiments were performed using COS-7 and HEK 293 cell
lines seeded into 12-well plates at 70% confluence. Twenty-
four hours later, 1 μg of pGL3/canonical_promoter plasmid,
pGL3/PAP plasmid or pGL3 control vector was co-
transfected with 0.05 μg pRL-TK vector into COS-7 and HEK
293 cells in triplicate using Lipofectamine 2000 Reagent
(Invitrogen, Milan, Italy) according to the manufacturer's
protocol. Cells were lysed with 200 μl passive lysis buffer
(Promega) 48 h after transfection. Cell lysates were vortexed
and briefly centrifuged to sediment cell debris. A 20-μl aliquot
of cell lysate was then assayed for luciferase activity using a
Lumat LB 9507 EG&G luminometer (Berthold Technologies
GmbH, Germany) and the DLR Luciferase Reporter Assay
System (Promega) according to the supplier's recommenda-
tions. A pGL3-control-promoter vector was included in all
assays. All experiments were repeated at least three times. Data
were expressed as M1/M2: RLUs firefly luciferase/RLUs
Renilla luciferase relative luciferase activity, defined as luci-
ferase activity normalized to the activity of Renilla luciferase,
used to correct for variability caused by differences in cell
viability or transfection efficiency.
Results and discussion
In an attempt to ascribe a functional meaning to the c.-1310CG
SNP located at position 40 346 645 on chromosome 22, we
ascertained from both the published literature (22) and from
online SNP databases (http://snp.ims.u-tokyo.ac.jp/cgi-bin/
MOLECULAR MEDICINE REPORTS  1:  805-812,  2008 807
Figure 1. The promoter region of XRCC6/Ku70 (chromosome 22, accession ref. no. NC_000022.9 NC_000022:40347241-40389998). The canonical
XRCC6/Ku70 promoter is represented in grey; the Ku70 putative alternative promoter (PAP) in yellow. Putative TATA box, CAAT and CAT motifs within the
PAP are shown in green. The 5'-UTR and the first exon of Ku70 are shown in light blue (ATG highlighted). Natural and putative splicing acceptor sites are shown
in dark blue; the polymorphic nucleotide at position -1310 is highlighted in green, with a bold enlarged font. A putative splice acceptor branch site is shown in
magenta. Functional and putative splicing donors are highlighted in red. The CREB (C-fos) transcription factor binding motif, altered by the G/- mutation in
linkage disequilibrium (LD) with the c.-1310CG SNP, is shown in a bold enlarged font. Transcription start sites (TSS) of published Ku70 mRNAs or ESTs are
shown in black boxes. The TSS of the EST DB181025, likely generated by a putative alternative promoter (28), is highlighted within the CREB (C-fos) binding
motif. Primer sequences used to analyze, by RT-PCR, the presence of alternative aberrant transcripts are underlined and numbered. Mutations in LD with the
c.-1310CG transversion, described in the NCBI LD Map, are highlighted in brown.
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SnpInfo.cgi?SNP_ID=IMS-JST020860, linked from the NCBI
SNP database: http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?
rs=2267437) that this mutation was attributed to the promoter
region of the XRCC6/Ku70 (Ku70) gene (NM_001469.3).
Since the c.-1310CG SNP was not located within an
exon but rather within the promoter region of Ku70, we hypo-
thesized that this mutation might be involved in the alteration
of the transcription or splicing processes. Examination of the
DNA sequence surrounding the nucleotide at position -1310
suggested that the CG transversion, being preceded by a
‘CAG’ motif and by a significant number of upstream
pirimidines, might be involved in the activation of a cryptic
splice acceptor site (Fig. 1).
To verify this hypothesis, we analyzed a region of 511 base
pairs surrounding the SNP by means of the Alex Dong Li's
Splice Site Finder, version 0.5 (http://violin.genet.sickkids.on.
ca/~ali/splicesitefinder.html), based on a modified algorithm
according to the matrix system of Shapiro and Senapathy (23).
The program did not identify a splicing site generated in the
region adjacent to the common ‘C’ variant of the polymor-
phism (Table I). However, when the sequence harboring the
‘G’ variant was inserted, the program identified a new splice
acceptor sequence, showing a total score of 81.1 and a putative
associated branch site lying 35 bases upstream of the mutant
nucleotide (Table I, Fig. 1).
This finding suggests that the c.-1310CG transversion
might activate a cryptic splicing acceptor within the 5'-end of
the Ku70 gene. To investigate the characteristics of this
cryptic splicing acceptor in greater detail, we analyzed the
site by information analysis. Using Schneider's Lab tools
(Molecular Information Theory Group, Center for Cancer
Research Nanobiology Program, National Cancer Institute,
Frederick, MD, USA; http://www.lecb.ncifcrf.gov/~toms/
delila.html), we generated sequence walkers to compare the
information content (and hence the ‘strength’) of the first
natural splice acceptor of Ku70 and of the putative cryptic
acceptor generated by the c.-1310CG transversion (Fig. 2).
Analysis showed that the first natural splicing acceptor of
Ku70 was characterized by relatively low information content
(3.1 bits), whereas the cryptic site containing the ‘C’ variant
of the polymorphism scored 2.3 bits. In the presence of the
c.-1310CG mutation, the splice site score was increased to
4.3 bits, a value higher than the one shown by the natural
competitor site (3.1 bits). Since, according to the information
theory, the minimum quantity of information required for
splicing was approximately 2.4 bits (24), and since splicing
likelihood was shown to be correlated to the amount of
information displayed by competing splicing sites (25), our
data predicted that the c.-1310CG mutation might be
responsible for the generation of alternatively spliced and
possibly aberrant transcripts of the Ku70 gene.
This hypothesis was supported by the evidence shown in
Fig. 3, which demonstrated that the c.-1310CG transversion
would generate a Holliday splicing configuration characterized
by optimal Watson-Crick base-pairing between the immature
RNA and the U5 and U1 snRNP-RNAs (26).
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Table I. Detection of splice acceptor sites in a 511-bp region surrounding the c.-1310C>G transversion.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Polymorphic variant: -1310C
Total acceptor sites detected: 7
Position Sequence, acceptor site Score Relative position Sequence, branch site Score Total splice site score
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
16 CACCCTCGTCGAAG|G 77.7 -20 TTTAC 72.8 150.5
152 GGCCCAAACTTCAG|A 72.7 -29 CTAAA 89.2 161.9
303 TCCCCCTCACCCAG|C 83.1 -25 CCCAC 67.8 150.9
330 AGCCGCCGGGCCAG|G 69.5 -33 CTCAC 92.1 161.6
342 AGGCCTTTGGACAG|G 77.2 -26 CTGAG 88.6 165.8
355 GGTCGTACACGTAG|A 67.8 -39 CTGAG 88.6 156.4
357 TCGTACACGTAGAG|C 66.1 -41 CTGAG 88.6 154.7
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Polymorphic variant: c.-1310G
Total acceptor sites detected: 8
Position Sequence Score Relative position Sequence, branch site Score Total splice site score
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
16 CACCCTCGTCGAAG|G 77.7 -20 TTTAC 72.8 150.5
152 GGCCCAAACTTCAG|A 72.7 -29 CTAAA 89.2 161.9
242 CCCACCTCGGCCAG|G 81.1 -32 GTGAG 67.0 148.1
303 TCCCCCTCACCCAG|C 83.1 -25 CCCAC 67.8 150.9
330 AGCCGCCGGGCCAG|G 69.5 -33 CTCAC 92.1 161.6
342 AGGCCTTTGGACAG|G 77.2 -26 CTGAG 88.6 165.8
355 GGTCGTACACGTAG|A 67.8 -39 CTGAG 88.6 156.4
357 TCGTACACGTAGAG|C 66.1 -41 CTGAG 88.6 154.7
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
805-812  10/10/08  15:57  Page 808
Moreover, information analysis allowed for the identi-
fication of two putative donor sites, characterized by relatively
high information content (7 bits; highlighted in Fig. 1).
To confirm these in silico findings, we performed RT-PCR
analysis in cell lines homozygous for the ‘C’ or ‘G’ poly-
morphic variants in order to identify potential alternative
fragments generated by aberrant splicing. Critical sequences
were amplified using a common reverse primer (primer 2; for
sequence see Materials and methods; highlighted in Fig. 1)
annealing with a specific sequence within Ku70 exon 2. Four
different forward primers (see Materials and methods and
Fig. 1), were designed to selectively detect aberrant fragments
generated by alternative splicing in case the newly charac-
terized SNP-activated splicing acceptor was functional. In
particular, primers 1-2 were designed to amplify a normal
264-bp transcript fragment embracing the 5'-UTR and exon 1;
primers 3-2, a 864-bp fragment embracing exon 1 and a newly
formed exonic region downstream of the splicing acceptor
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Figure 2. Lister map, sequence walkers and information content of the first natural splicing acceptor of XRCC6/Ku70 (top). The information content of the
putative cryptic splicing acceptor containing the ‘C’ variant of the SNP is shown in the middle sequence. Bottom, putative cryptic splicing acceptor activated
by c.-1310CG transversion. The boxed bases in the sequence walkers represent the last intronic guanine; the base immediately downstream is -1310C
(middle sequence) or mutant -1310G (bottom sequence). Schneider's Lab Tools were used to produce the lister map and sequence walkers, and to calculate the
information content of these splice sites.
Figure 3. Schematic representation of the formation of a Holliday-like structure during assembly of the mammalian spliceosome. The c.-1310CG transversion
(left) generates a Holliday splicing configuration characterized by optimal Watson-Crick base-pairing between the immature RNA and the U5 and U1 snRNP-
RNAs. The right panel shows base-pairing and interactions between RNA and U5/U1 snRNP-RNAs, reproduced according to the model described by Steitz (26).
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generated by the c.-1310CG transversion; primers 4-2, a
1922-bp fragment comprising exon 1 and a hypothetical
5'-UTR transcribed downstream of a putative promoter region
upstream of the SNP (described in the following section) and
primers 2-5, a 919-bp fragment comprising exon 1 and a
putative intronic region located upstream of the hypothetic
SNP-activated cryptic splice acceptor.
Whereas primers 1-2 allowed for the amplification of a
‘normal’ 264-bp sequence (Fig. 4), we were unable to detect in
the GM12802 G/G homozygous cell line fragments suggesting
the presence of alternative transcripts, indicating the activation
of the cryptic splicing site at the site of the SNP. However, the
presence of a 2-5 fragment of ~1,000 bp, detected by repeated
RT-PCR reactions (Fig. 4), was suggestive of the presence of
a transcript originating from an unknown promoter region
located upstream of the canonical promoter of Ku70, described
by Hosoi et al (27).
Analysis of a Ku70 EST database indicated the presence
of longer transcripts, extending well upstream of the ‘normal’





transcription start site of this EST lies 166 bases upstream
of known ‘+1’ sites of Ku70 (Fig. 1). This specific transcript
of Ku70 was identified in the context of a research project
aimed at isolating new 5'-extended ESTs that would likely be
generated by PAPs (28). In fact, it is estimated that 52% of
human genes may be subject to regulation by a PAP (28).
This is of interest because the presence of an additional
promoter region upstream of the TATA-less Sp1 cluster,
acknowledged to canonically drive the transcription of Ku70,
would justify the presence and activity of an alternative SNP-
generated splicing site upstream of the Sp1 cluster.
To identify a PAP upstream of the c.-1310CG SNP, we
submitted a sequence spanning 4,000 bp upstream of the
canonical promoter of Ku70 to the Promoter Scan program
(http://www-bimas.cit.nih.gov/molbio/proscan/) of the Center
for Information Technology, National Institutes of Health.
The program detected the ‘canonical’ TATA-less Ku70 pro-
moter, and assigned it a score of 67.66. Interestingly, the
program also detected a promoter region 1,297 bp upstream
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Figure 4. Agarose gel showing RT-PCR fragments obtained using different
forward primers to detect alternative transcripts within the 5' region of the
XRCC6/Ku70 gene in the GM12802 cell line. The arrow in the lane showing
the 5-2 fragment indicates the position of the 1-kb product of a putative
transcript originating from an unknown promoter region upstream of the
canonical promoter of Ku70; the arrow in the lane showing the 1-2 RT-PCR
fragment indicates the position of a ‘normal’ fragment of 264 bp embracing
the 5'-UTR and exon 1 of XRCC6/Ku70. In lane 3-2 and 4-2, aspecific
amplicons are visible. These bands disappeared when the experiment was
replicated.
Figure 5. Analysis of the region upstream of the XRCC6/Ku70 gene, performed
using the Promoter Scan program (http://www-bimas.cit.nih.gov/molbio/
proscan/).
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of the previous one, to which the maximum score of 100 was
assigned (Fig. 5). This was mostly due to the presence of a
unique Ig_dc sequence, exclusively found in human gene
promoters. Analysis of the newly detected PAP showed the
presence of a putative TATA box preceded by a CAAT motif
(~40 bp upstream of the TATA box) and followed (20 bp
downstream) by a CAT motif (highlighted in Fig. 1).
To experimentally ascertain the activity of the newly
found PAP, we amplified a fragment of 748 bp using PCR,
embracing the canonical promoter of Ku70 (27) and a 601-bp
fragment corresponding to the PAP. Fragments were sub-
sequently cloned upstream of a luciferase reporter gene
within a pGL3 vector specifically designed for functional
identification and characterization of promoter elements. Fig. 6
shows that, whereas the canonical Ku70 promoter induced a
strong expression of firefly luciferase, the putative Ku70
alternative promoter failed to act as a transcriptional activator
of the reporter gene.
In summary, although we performed a very promising
in silico analysis that suggested the existence of a relatively
strong alternative splicing acceptor and pointed to the activity
of a strong PAP of XRCC6/Ku70, experimental data ruled out
the hypothesis of the involvement of the c.-1310CG mutation
in alternative/aberrant splicing of Ku70 gene transcripts. Thus,
care must be taken when translating data obtained in silico to
experimental evidence. 
Since Ku70 is a key protein involved in DNA DSB repair,
we investigated whether the c.-1310CG mutation would
impair the function of Ku70 and in turn render the GM12802
G/G homozygous cell line more sensitive to DNA damaging
agents. The cytokinesis-block micronucleus assay revealed a
slight increase in radiosensitivity of GM12802 cells as com-
pared to a panel of 23 homozygous (C/C) EBV-immortalized
lymphoblastic cell lines (Fig. 7).
To explore an alternative role of the c.-1310CG SNP in
the regulation of Ku70 expression, we hypothesized that this
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Figure 6. Analysis of firefly luciferase expression in COS-7 and HEK 293 cells, expressed as RLU/s firefly luciferase/RLU/s Renilla luciferase normalization
ratio. The pGL3/canonical_promoter or pGL3/PAP plasmids, containing the Ku70 canonical promoter or the PAP, respectively, or the pGL3 control vector,
were co-transfected with the pRL-TK vector into COS-7 and HEK 293 cells; 48 h after transfection, cell lysates were assayed for luciferase activity using the
Dual Luciferase Reporter Assay System as described in Materials and methods. 
Figure 7. Frequency distribution of micronucleus formation (micronucleus-bearing cells/500 binucleated cells) in 23 EBV-immortalized control cell lines
homozygous for the ‘C’ variant of the c.-1310C>G transversion in the XRCC6/Ku70 gene. The micronucleus score of the GM12802 EBV-immortalized cell
line, homozygous for the ‘G’ variant of the polymorphism, is indicated with an arrow.
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mutation might be in linkage disequilibrium (LD) with other
mutations or SNPs involved in the regulation of gene
expression. The existence of LD between the c.-1310CG
and other mutations in Ku70 has also been hypothesized by
Tsai et al (22) and Bau et al (29).
Analysis of the LD maps published in the NIH-NCBI
database (http://www.ncbi.nlm.nih.gov/SNP/GeneGt.cgi?
geneID=2547) showed that the c.-1310CG transversion is
in strong LD with a number of SNPs located in the canonical
promoter region of Ku70 (Fig. 1). In particular, the rs11342289
deletion (G/-) is placed between a CRE (TGACGT) and a SP1
site (GGGGCGGG, Fig. 1). Notably, the mutant guanine is
part of a c-fos binding site (TGACGTAGG) (30), as shown in
Fig. 1. The rare variant of this SNP (guanine deletion) could
affect the generation of Ku70 transcripts.
The rs28384707 (C/A) SNP, in strong LD with the
c.-1310CG mutation, is located at the exact position where
most Ku70 mRNA transcription start sites have to date been
described (Fig. 1). This polymorphism may also affect the
transcription efficiency of Ku70. Other SNPs in LD with the
c.-1310CG mutation (e.g., rs28384708, rs28384711), located
in intronic regions, may also affect the expression of Ku70 in
different ways. However, this does not exclude LD with
additional, as yet unidentified, SNPs located within exonic
regions. Research is underway to identify exonic SNPs
throughout the Ku70 gene and to characterize the LD of these
polymorphisms with the c.-1310CG transversion or with
other disease-associated mutations.
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